부정맥의 약물요법: Overview

부정맥의 약물요법: Overview

2018년에 European Heart Rhythm Association (EHRA)/European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology/Heart Rhythm Society (HRS)/Asia-Pacific Heart Rhythm Society (APHRS)/International Society of Cardiovascular Pharmacotherapy (ISCP)가 공동으로 발표한 "Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document"에 부정맥의 약물요법에 대한 일반적인 지침이 일목요연하게 잘 정리되어 있습니다. 해당논문을 참조하길 바랍니다.

예시: Regular tachycardia(혈역학적으로 안정된 경우)의 급성기 치료

심전도 소견		권고항목	권고등급(Class)	증거수준
Narrow QRS-complex tachycardia		Vagal manoeuvres	I	B
		Adenosine	I	A
		Verapamil/diltiazem	I	A
		Beta-blockers	IIb	C
		Amiodarone	IIb	C
		Digoxin	IIb	C
Wide QRS-complex tachycardia	SVT and BBB	See above
	Pre-excited SVT	Flecainide	I	B
		Ibutilidea	I	B
		Procainamide	I	B
		DC cardioversion	I	C
	Of unknown origin and preserved LV function	Procainamide	I	B
		Sotalol	I	B
		Amiodarone	I	B
		DC cardioversion	I	B
		Lidocaine	IIb	B
		Adenosine	IIb	C
		Beta-blockers	I	C
		Verapamil	I	B
	Of unknown origin and poor LV function	Amiodarone	I	B
		DC cardioversion	I	B
		Lidocaine

참고자료

Dan G-A, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace 2018;20(5):731–732an.

대한임상진료학회 강사 모집

1. 강의 주제

2. 강의 성격

부정맥의 약물요법: Overview 구독